Abstract:Topic: 22. Stem cell transplantation - Clinical Background: Patients suffering from severe acquired aplastic anemia (SAA) are at a high risk of death without prompt and appropriate treatment. Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) has drawn increasing interest as a curative option for SAA. However, graft failure (GF) and severe graft-versus-host disease (GvHD) are two primary obstacles to successful haplo-HSCT. Over decades, G-CSF/ antithymocyte globulin (ATG)-based protocol (the Beijing Protocol) has achieved favorable engraftment and survival outcomes both as an upfront and salvage treatment in SAA patients, whereas the incidence of GvHD is relatively high. Apart from the Beijing Protocol, high-dose post-transplant cyclophosphamide (HD-PTCy, the Baltimore regimen) has been successfully used in haplo-HSCT for SAA, and an inspiring decrease in aGVHD albeit with somewhat high rates of GF has been consecutively reported. Therefore, it is reasonable to modify the current two transplant protocols to exploit their strength and avoid unfavorable conditions. Aims: In this study, we modified the conventional Beijing Protocol: retaining the standard dose of ATG from Beijing protocol to provide sufficient immunosuppression; dividing the full-dose Cy (200 mg/kg in total) was divided into 42.75 mg/kg Cy on day -5 to day -2 and LD-PTCy (14.5 mg/kg on days +3 and +4/+5), hoping to reduce the incidence of severe aGVHD and to guarantee successful and stable engraftment. Methods: Between August 2020 and August 2022, 17 patients diagnosed with SAA accepting haplo-HSCT under the PTCy regimen at Peking University People’s Hospital were enrolled in this study. Here we reported the clinical outcomes of 17 patients who received this modified protocol. Results: Seven patients were males (41.18%) and the median age of these patients was 12 (range, 5-39) years old. The median follow-up was 522 days (range, 138-859 days). No patient developed primary graft failure. All patients achieved neutrophil and platelet engraftment at median times of 12 days (range, 11–20 days) and14 days (range, 8-36 days). During our follow-up, no patients developed grade Ⅲ-Ⅳ aGvHD. The cumulative incidence of grade ⅡaGvHD at 100 days was 23.5% (95% CI, 1.0%-46.0%). Four patients (23.5%) developed chronic GvHD of skin or eyes and all of which were mild. All patients are alive by the end of the follow-up, with a failure-free survival rate of 100%. Four (23.5%) patients developed grade Ⅱ bladder toxicity, two (11.8%) patients developed grade Ⅱ cardiotoxicity. The rate of cytomegalovirus (CMV) reactivation was 82.4% (95% CI, 64.3%-100%). The rate of Epstein-Barr virus (EBV) reactivation was 16.7% (95% CI, 0%-35.7%). No CMV disease and post-transplantation lymphoproliferative disorder (PTLD) occurred among these patients. Summary/Conclusion: In conclusion, our data revealed that it is feasible and effective to use the G-CSF/ATG/LD-PTCy protocol in haplo-HSCT for SAA. With RIC preparative regimen and the use of LD-PTCy, the incidence of severe GVHD was reduced and successful and stable engraftment was achieved.Figure 1 Keywords: Acute graft-versus-host disease, Cyclophosphamide, Aplastic anemia, Haploidentical stem cell transplantation

A Modified Conditioning Regimen Based on Low‐dose Cyclophosphamide and Fludarabine for Haploidentical Hematopoietic Stem Cell Transplant in Severe Aplastic Anemia Patients at Risk of Severe Cardiotoxicity

Fludarabine- and Low-Dose Cyclophosphamide-Based Conditioning Regimens for Unmanipulated Hematopoietic Cell Transplantation from Unrelated Donors and Matched Siblings in Patients with Fanconi Anemia: Results from the Cbmtr

[Study on Unrelated Donor Allogeneic Bone Marrow Transplantation with Bu-CY2 Conditioning Regimen for Myelodysplastic Syndrome].

Busulfan and Cyclophosphamide for Hemopoietic Stem Cell Transplantation from Related and Unrelated Donors in Patients with Myelodysplastic Syndrome

Fludarabine and antithymocyte globulin-based conditioning regimen combined with post-transplantation cyclophosphamide for haploidentical allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia and myelodysplastic syndrome

Control Study of Fludarabine Instead of Cyclophosphamide in Modified Busulfan-Cyclophosphamide As a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Treatment of Acute Leukemia

Unmanipulated Haploidentical Haematopoietic Cell Transplantation with Radiation-Free Conditioning in Fanconi Anaemia: A Retrospective Analysis from the Chinese Blood and Marrow Transplantation Registry Group

[Reduced Intensity of BuCy Conditioning Regimen for Transplantation in the Treatment of Malignant Hematologic Diseases].

Long-Term Efficacy Analysis of Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Acute Myeloid Leukemia Using Melphalan Instead of Cyclophosphamide As a Myeloablative Conditioning Regimen

Low-dose Post-Transplant Cyclophosphamide with G-CSF/ATG Based Haploidentical Protocol Provides Favorable Outcomes for SAA Patients.

Graft-Versus-Host Disease Following Myeloablative Busulfan Plus Fludarabine And Busulfan Plus Cyclophosphamide For Allogeneic Hematopoietic Stem Cell Transplantation In Acute Myeloid Leukemia In First Complete Remission

Combination of Busulfan with Increased-Dose of Fludarabine As Conditioning Regimen for MDS and MDS-AML Patients with Allo-Hsct

Prospective Study of a Modified Post-Transplantation Cyclophosphamide Regimen for Severe Aplastic Anemia Patients with HLA-Haploidentical Transplantation

Outcomes following HSCT using fludarabine replacing cyclophosphamide as a new preconditioning regimen for treatment of hematologic malignancies

Myeloablative Buflu Conditioning Is Well Tolerated And Can Achieve Even Better Outcomes In Hla-Mismatched Donor Transplantation For Intermediate- And High-Risk Aml Patients In Complete Remission

[The Efficacy and Safety of Modified Busulfan/fludarabine Conditioning Regimen in Elderly or Drug-Intolerable Patients with Hematologic Malignancies].

Feasibility of reduced-dose posttransplant cyclophosphamide and cotransplantation of peripheral blood stem cells and umbilical cord-derived mesenchymal stem cells for SAA

P1293: LOW-DOSE POST-TRANSPLANT CYCLOPHOSPHAMIDE WITH G-CSF/ATG BASED HAPLOIDENTICAL PROTOCOL PROVIDES FAVORABLE DECREASE IN ACUTE GRAFT-VERSUS-HOST DISEASE FOR SAA PATIENTS

Evaluate the Efficacy of Myeloablative Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myelogenous Leukemia at BTH, Vietnam

Unmanipulated Haploidentical Transplantation Conditioning with Busulfan, Cyclophosphamide and Anti-Thymoglobulin for Adult Severe Aplastic Anaemia

Efficacy of a Modified Post-Transplant Cyclophosphamide Regimen for Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients with Severe Aplastic Anemia: A Prospective Study